U.S. markets closed

Acacia Research Corporation (ACTG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.95+0.04 (+0.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.91
Open5.91
Bid5.94 x 1100
Ask5.95 x 1300
Day's Range5.83 - 6.03
52 Week Range2.23 - 9.09
Volume442,319
Avg. Volume990,516
Market Cap293.213M
Beta (5Y Monthly)0.56
PE Ratio (TTM)3.86
EPS (TTM)1.54
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 04, 2015
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Shareholder broadside at biotech investor Arix’s board
    The Telegraph

    Shareholder broadside at biotech investor Arix’s board

    Arix Bioscience, the biotechnology investor backed by restaurant tycoon Richard Caring and biotech entrepreneur Sir Christopher Evans, has been forced to halt two board appointments after its largest shareholder called for a total overhaul in a scathing letter. Mayfair-based Arix has had to pause the planned hire of two directors due to join the business this month after Acacia Research, an American investor advised by Neil Woodford, said in a damning public letter that the firm faced “seemingly uncontrollable board tumult” and was being led by a “woefully inadequate investment group” after 18 director departures in five years. In response, Arix said it had an experienced board and was already building its investment team in the UK and the US. Fallen fund manager Mr Woodford is not advising Acacia on this saga, people familiar with the matter said. Arix was due to welcome Dr Axel Wieandt, a former Morgan Stanley and Deutsche Bank banker, on to the board alongside biotech expert James Noble. However it has told investors that while the pair remain “highly qualified” the appointments are on hold while it reviews parts of the business including “the question of board composition”.

  • Business Wire

    Acacia Research Reports Fourth Quarter and Full-Year 2020 Financial Results

    Acacia Research Corporation (Nasdaq: ACTG) today reported results for the three and 12-month period ended December 31, 2020.

  • Acacia Research to Release Fourth Quarter and Year-end 2020 Financial Results
    Business Wire

    Acacia Research to Release Fourth Quarter and Year-end 2020 Financial Results

    Acacia Research Corporation ("Acacia" or "the Company") (NASDAQ: ACTG) announced today it will release its fourth quarter and year-end 2020 financial results on Monday, March 29, 2021 at 8:00 a.m. ET/ 5:00 a.m. PT.